Last reviewed: June 30, 2026 Last updated: June 30, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Soni N, Reddy BVK, Kumar P (2014) GLT-1 transporter: an effective pharmacological target for various neurological disorders
The great improvement detected in ED degree category should be regarded with caution considering that, in the l-ARG cohort, only 24% of patients, mainly belonging to the baseline category of mild ED, reached IIEF-6 scores compatible with absence of ED, whereas the majority of patients improved the category by remaining within the range of ED
Summary GHK-Cu is often missing from injury recovery protocols not because it lacks biological activity, but because injury repair is phase-dependent